Upon discovering irregularities in a resident's drug regimen, the consultant pharmacist should inform which parties?

Upon discovering irregularities in a resident's drug regimen, the consultant pharmacist should inform which parties?

• A. Attending physician and family
• B. Attending physician
• C. DON, Medical Director, and attending physician
• D. DON and Medical Director

Answer: (C)

Effective communication and escalation when medication irregularities are found. When a consultant pharmacist identifies irregularities in a resident's drug regimen, the right move is to promptly inform the attending physician, the Director of Nursing, and the Medical Director. The attending physician is responsible for the medical orders and adjustments; the DON oversees nursing care and medication administration processes; the Medical Director provides medical oversight and ensures alignment with facility policies and standards. This trio ensures quick clinical assessment, safe correction, complete documentation, and accountability across the care team. It also supports patient safety by involving both prescriber and leadership in the change process. In most cases, informing the family is not appropriate for routine clinical management due to privacy and because they are not part of the decision-making chain unless the patient or legally authorized representative requests information.

Effective communication and escalation when medication irregularities are found. When a consultant pharmacist identifies irregularities in a resident's drug regimen, the right move is to promptly inform the attending physician, the Director of Nursing, and the Medical Director. The attending physician is responsible for the medical orders and adjustments; the DON oversees nursing care and medication administration processes; the Medical Director provides medical oversight and ensures alignment with facility policies and standards. This trio ensures quick clinical assessment, safe correction, complete documentation, and accountability across the care team. It also supports patient safety by involving both prescriber and leadership in the change process. In most cases, informing the family is not appropriate for routine clinical management due to privacy and because they are not part of the decision-making chain unless the patient or legally authorized representative requests information.